As such, physicians should aim to follow a patient-centered approach to postoperative care that educates patients on the rationale, risks, and benefits of alternative treatments.17

Postoperative care is critical to maintaining sinus surgery benefits in patients with chronic rhinosinusitis (CRS).1,2 Although oral corticosteroids (OCS) have an established role in postoperative care, and in many cases may be the right treatment for CRS patients, it's important to consider its challenges.3,4

CONSIDER THE POTENTIAL RISKS5-12

• Adrenal suppression

• Bone loss

• Gastrointestinal symptoms

• Hyperglycemia

• Infections

• Ophthalmic complications

• Psychiatric symptoms (eg, irritability and mood swings)

• Weight gain

CONSIDER THE UNKNOWNS2,5,9,10,13-16

• 1 in 3 ENT patients are noncompliant to prescribed therapies

• Individual variability exists in dose sensitivity and time to medication-related complications

• It is unknown if short-term OCS use provides increased safety over long-term use

Find out how PROPEL can improve your sinus surgery outcomes ...

Strategize your chronic rhinosinusitis postoperative care plan

The PROPEL sinus implants are indicated to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age after sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. Rx only. References: 1. Sedaghat AR. Am Fam Physician. 2017;96(8):500-506. 2. Vennik J, et al. BMJ Open. 2018;8(12):e022643. 3. Rosenfeld RM, et al. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1-S39. 4. Poetker DM, et al. Int Forum Allergy Rhinol. 2013;3(2):104-120. 5. Wilson AM, et al. Chest. 1998;114(4):1022-1027. 6. van Staa TP, et al. Osteoporos Int. 2002;13(10):777-787. 7. Messer J, et al. N Engl J Med. 1983;309(1):21-24. 8. Gulliford MC, et al. Diabetes Care. 2006;29(12):2728-2729. 9. Stuck AE, et al. Rev Infect Dis. 1989;11(6):954-963. 10. Derby L, et al. J Allergy Clin Immunol. 2000;105(5):912-916. 11. Bolanos SH, et al. Ann Allergy Asthma Immunol. 2004;92(5):500-505. 12. Rogers CC, et al. Transplant Proc. 2005;37(2):800-801. 13. Tamblyn R, et al. Ann Intern Med. 2014;160(7):441-450. 14. Vennik J, et al. BMJ Open. 2019;9(4):e022644. 15. Waljee AK, et al. BMJ. 2017;357:j1415. 16. Motegi R, et al. Sinusitis. doi:10.3390/sinusitis3020005. 17. Poetker DM, et al. Int Forum Allergy Rhinol. 2012;2(2):95-103. 18. PROPEL [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013. 19. PROPEL Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016. 20. PROPEL Contour [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016. 21. Smith TL, et al. Laryngoscope. 2016;126(12):2659-2664.

INTERSECT ENT and PROPEL are registered trademarks of Intersect ENT, Inc. in the United States and other countries.

©2020 Intersect ENT, Inc. All rights reserved. MPM-11694 Rev 1.0

�Explore�the�LOCAL�and�ROBUST�benefits�of�the� PROPEL�family�of�implants�at�PROPELOpens.com

* The PROGRESS study was a prospective, randomized, blinded, intra-patient control study in 80 patients receiving frontal sinus surgery with PROPEL Mini placement compared to surgery alone. PROPEL Mini was removed at Day 21 to facilitate blinded independent assessment at Day 30 following surgery.21 †Postoperative interventions was a composite primary endpoint that included surgical intervention required to separate an adhesion and/or oral steroid intervention to resolve recurrent frontal sinus inflammation, edema, and/or polyp recurrence. ‡Judged by an independent reviewer. §Secondary endpoints judged by on-site clinical investigators.

ARMED WITH PROPEL

Add PROPEL to your postoperative care action plan PROPEL family of implants feature an innovative 2-in-1 mechanism that opens the sinuses while LOCALLY delivering mometasone furoate, a potent corticosteroid, directly where it is needed18-20

PROPEL�Mini�reduces�the�need�for�oral�steroid�interventions19§

Perc

enta

ge o

f Sin

uses

(%)

60

40

20

0Surgery alone

(N=80)Surgery + PROPEL Mini

(N=80)

34.2% vs 15.2%P=0.0015

PROPEL + YOUR PATIENTS = IMPROVED OUTCOMES

38% REDUCTION (62.7% vs 38.8%; P=0.0070) in the need for postoperative�interventions19†‡

RELATIVE REDUCTIONS REPORTED WITH PROPEL MINI AT DAY 30 FOLLOWING FRONTAL SINUS SURGERY*:

75% REDUCTION (16.0% vs 4.0%; P=0.0225) in the need for surgical�interventions19§

56% REDUCTION